Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immunology

Set Alert for Immunology

AstraZeneca’s IBD Hopes Deflated Amid Evolving Market And Pipeline Competition

The major’s attempt to break into Crohn’s disease and ulcerative colitis has been cut short as a highly competitive market and pipeline, intensified by the entrance of biosimilars, renders further development of brazikumab impractical.

Gastrointestinal Immune Disorders

Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade

The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.

Immune Disorders Approvals

AbbVie's Rinvoq Succeeds Against The Odds In Phase II Lupus Trial

Despite a troubled history of JAK inhibitors in lupus trials, AbbVie’s Rinvoq has hit the mark in a mid-stage study of the condition, shifting focus to a pivotal program that could expand the blockbuster drug’s reach.

Clinical Trials Immune Disorders

UCB Holds Breath Amid Concerns Of Second FDA Rejection Of Bimzelx

The US Food and Drug Administration has published a report after an inspection of UCB’s Belgian facility where Bimzelx is manufactured and the findings suggest that a long-awaited approval for the psoriasis drug should not be taken for granted.

Complete Response Letters Immune Disorders

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen’s Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan’s pharma firms; and new Tagrisso data lift AstraZeneca.

Business Strategies Commercial

Rinvoq Approved For Crohn’s Disease In Pivotal Year For AbbVie’s Immunology Business

US FDA approval in Crohn’s disease further boosts the revenue potential for Rinvoq as AbbVie navigates a period of declining sales overall due to the introduction of US biosimilars for Humira. 

Approvals Growth

Teva Establishes Four Pillars To Prop Up Its Return-To-Growth Strategy

New CEO Richard Francis outlined the company’s new focus on innovative brands, funded by a portion of capital reallocated from Teva’s generics business.

Strategy Growth

X4 Pharma’s Success After Cutbacks Will Comfort Hard-Hit Biotechs

X4 Pharma has shown that cutting back and focusing on a lead asset can work but mavorixafor’s first-in-class status and efficacy profile is not common.

Commercial Companies

Novartis Confident About Transforming CSU Landscape

With its BTK inhibitor remibrutinib advancing through Phase III trials and work getting started on a CAR-T therapy for lupus, Novartis’s Marie-France Tschudin tells Scrip that the Swiss major’s immunology pipeline is in a healthy state.

Immune Disorders Research & Development

Gilead Adds Inflammation Targets To Its 2020 R&D Collaboration With Arcus

Deal Snapshot: Already partnered on an anti-TIGIT drug and other immuno-oncology candidates, the firms will team up further on four targets in inflammatory disease.

Deals Business Strategies

Investors Impressed With Dualyx Tregs Plans

The proceeds from the series A will be used to progress Dualyx’s preclinical program DT-001, which targets "the highly attractive TNF receptor 2 (TNFR2), widely regarded as a master control switch in immune modulation."

Financing Immune Disorders

Novartis Committed To Carving Out More Indications For Cosentyx

The Swiss behemoth’s chief commercial officer Marie-France Tschudin tells Scrip that the firm will keep expanding Cosentyx into disease areas “that have been a little bit neglected.”

Immune Disorders Business Strategies
See All
UsernamePublicRestriction

Register